These results suggest that PRKCQ-AS1 induces tamoxifen resistance by upregulating MKP1 and activating MAPK/JNK pathway, which reduces tamoxifen treatment-induced apoptosis in ER + breast cancer cells. Here, PRKCQ is linked to breast carcinoma.